专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100056585A1 N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B 有权
标题翻译： N-（2-氨基苯基）-4- [N-（吡啶-3-基） - 甲氧基羰基 - 氨基甲基] - 苯甲酰胺（MS-275）多晶型B
公开(公告)号：US20100056585A1
公开(公告)日：2010-03-04
申请号：US12549458
申请日：2009-08-28
申请人： Matthias Schneider , Michael Gottfried , Jens Geisler , Gabriele Winter
发明人： Matthias Schneider , Michael Gottfried , Jens Geisler , Gabriele Winter
IPC分类号： A61K31/4406 , C07D213/46 , A61P35/00 , A61P37/00 , A61P17/00
CPC分类号： A61K31/4406 , C07D213/30 , Y02A50/411
摘要： The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula Iis described, as well as the process for the production of said compound, and its use as a medicament for the treatment of selected diseases.
摘要翻译：描述了式I的N-（2-氨基苯基）-4- [N-（吡啶-3-基）甲氧基 - 碳氨基甲基]苯甲酰胺（MS-275）的结晶多晶型B，以及制备所述化合物及其作为用于治疗所选疾病的药物的用途。

12. 发明授权

US07598378B2 Method for the production of 4-(4-aminophenyl)-3-morpholinone 有权
标题翻译： 4-（4-氨基苯基）-3-吗啉酮的制备方法
公开(公告)号：US07598378B2
公开(公告)日：2009-10-06
申请号：US10571364
申请日：2004-09-09
申请人： Christian Thomas , Mathias Berwe , Alexander Straub
发明人： Christian Thomas , Mathias Berwe , Alexander Straub
IPC分类号： C07D413/14 , C07D295/135
CPC分类号： C07D265/32 , C07D409/14
摘要： The present invention relates to a process for preparing 4-(4-aminophenyl)-3-morpholinone by reacting 4-(4-nitrophenyl)-3-morpholinone with hydrogen in the presence of a hydrogenation catalyst, characterized in that the reaction is effected in an aliphatic alcohol.
摘要翻译：本发明涉及通过在氢化催化剂存在下使4-（4-硝基苯基）-3-吗啉酮与氢气反应来制备4-（4-氨基苯基）-3-吗啉酮的方法，其特征在于进行反应在脂肪醇中。

13. 发明授权

US07598263B2 Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them 失效
标题翻译：氰基喹啉衍生物，它们的制备方法，用途以及包含它们的药物
公开(公告)号：US07598263B2
公开(公告)日：2009-10-06
申请号：US11765813
申请日：2007-06-20
申请人： Olaf Prien , Knut Eis , Wolfgang Schwede , Judith Guenther , Dieter Zopf
发明人： Olaf Prien , Knut Eis , Wolfgang Schwede , Judith Guenther , Dieter Zopf
IPC分类号： A61K31/435 , C07D215/00
CPC分类号： C07D495/04
摘要： The present invention relates to a quinoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
摘要翻译：本发明涉及具有通式（A）的喹啉衍生物：其中R1，R2，X，Y和Z在说明书和权利要求中表示，通式（A）的化合物用于各种病症的治疗，以及通式（A）的化合物的制备。

14. 发明申请

US20090240142A1 SYSTEMS AND METHOD OF DELIVERING FLUIDS TO A PATIENT OF VARYING CONCENTRATION 有权
标题翻译：将流体输送给变化浓度的患者的系统和方法
公开(公告)号：US20090240142A1
公开(公告)日：2009-09-24
申请号：US12302907
申请日：2007-06-06
申请人： Ruediger Lawaczek , John F. Kalafut
发明人： Ruediger Lawaczek , John F. Kalafut
IPC分类号： A61B6/00
CPC分类号： A61K49/0452 , A61K49/0438 , A61K49/0447 , A61K49/18 , A61M5/007 , A61M31/005
摘要： A method for injection of an imaging contrast into a patient, includes: a. in a first phase, injecting a fluid having a first concentration of contrast agent for a first period of time; and b. in a second phase, injecting a fluid having a second concentration of contrast agent for a second period of time. The osmolarity of the second phase is higher than the osmolarity of the first phase. In several embodiments in which the contrast agent of the first phase is of the same composition as the contrast agent of the second phase, the second concentration can be higher than the first concentration. The first phase can, for example, precede the second phase. The method can further include: c. in a third phase, subsequent to the second phase, injecting a fluid having a third concentration of contrast agent for a third period of time. The osmolarity of the third phase is lower than the osmolarity of the second phase. In embodiments in which the composition of the contrast agent of the third phase is the same as the composition of the contrast agent of the second phase, the third concentration can be lower than the second concentration. The fluid injected in the first phase can, for example, be closer to the osmolarity of blood that the fluid injected in the second phase and can even be generally iso-osmolar to blood plasma (for example, within 20% or even 10% or less of the osmolarity of blood plasma of the patient). Likewise, the fluid injected in the third phase can be closer to the osmolarity of blood plasma that the fluid injected in the second phase and can even be generally iso-osmolar to blood.
摘要翻译：一种用于将成像对比度注射到患者体内的方法包括：a。在第一阶段中，将具有第一浓度的造影剂的流体注射第一时间段; 和b。在第二阶段中，将具有第二浓度的造影剂的流体注射第二时间段。第二相的渗透压高于第一相的渗透压浓度。在其中第一相造影剂与第二相造影剂具有相同组成的几个实施方案中，第二浓度可高于第一浓度。第一阶段可以例如在第二阶段之前。该方法还可以包括：c。在第三阶段中，在第二阶段之后，将具有第三浓度的造影剂的流体注射第三时间段。第三相的渗透压低于第二相的渗透压。在第三相造影剂的组成与第二相造影剂的组成相同的实施方案中，第三浓度可低于第二浓度。在第一阶段注射的流体可以例如更接近在第二阶段中注入的流体的血液的渗透压，甚至可以通常与血浆等渗（例如在20％或甚至10％以内）较少的患者血浆渗透压）。同样地，注入第三相的流体可以更接近在第二相中注入的流体的血浆的渗透压，甚至可以通常与血液等渗。

15. 发明授权

US07582666B2 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotics 失效
标题翻译：取代的2-氧代-3-苯基-5-羰基氨基甲基-1,3-恶唑啉及其作为抗凝血和抗血栓的用途
公开(公告)号：US07582666B2
公开(公告)日：2009-09-01
申请号：US11394543
申请日：2006-03-31
申请人： Alexander Straub , Thomas Lampe , Josef Pernerstorfer , Elisabeth Perzborn , Jens Pohlmann , Susanne Rohrig , Karl-Heinz Schlemmer
发明人： Alexander Straub , Thomas Lampe , Josef Pernerstorfer , Elisabeth Perzborn , Jens Pohlmann , Susanne Rohrig , Karl-Heinz Schlemmer
IPC分类号： A61K31/422 , A61K31/5377 , C07D413/10 , C07D413/14 , C07D263/20
CPC分类号： C07D413/10 , C07D413/14
摘要： The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing the compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases.
摘要翻译：本发明涉及血液凝固领域，更具体地说，涉及通式（I）的新型化合物，涉及用于制备化合物的方法及其作为用于预防和/或治疗疾病的药物中的活性成分的用途。

16. 发明申请

US20090163891A1 CATHETER HAVING A CORE WIRE AND A LOW PROFILE BOND 有权
标题翻译：具有核心线和低剖面粘结的导管
公开(公告)号：US20090163891A1
公开(公告)日：2009-06-25
申请号：US12339686
申请日：2008-12-19
申请人： Benjamin T. Ewing , Gregory G. Brucker , Scott A. Bednar , John R. Periard
发明人： Benjamin T. Ewing , Gregory G. Brucker , Scott A. Bednar , John R. Periard
IPC分类号： A61M25/00
CPC分类号： A61M25/104 , A61M25/1034 , A61M25/1036 , A61M2025/0034 , A61M2025/0036 , A61M2025/0037 , A61M2025/004 , A61M2025/0063 , A61M2025/0183
摘要： A catheter having a shaft that has at least two spaced-apart lumens is disclosed. A retractable core wire is disposed within at least one of the lumens. The retractable core wire is manipulated by the user to impart variable stiffness to the shaft as the core wire is retracted and extended within the lumen. A catheter having substantially low profile bonds at the junctions where an inflatable balloon is attached to the catheter is also disclosed. The low profile bonds are created by recesses extending around the circumference of the distal end of the shaft, the proximal and distal ends of a stem, and the proximal end of a tip. The catheter having the low profile bond optionally has either a retractable or an embedded core wire. In examples, the catheter has at least one component formed from, co-extruded with, or coated with a lubricious material or a hydrophilic material.
摘要翻译：公开了具有至少两个间隔开的腔的轴的导管。可缩回的芯线布置在至少一个管腔内。当芯线在管腔内缩回并延伸时，可伸缩的芯线被用户操纵以赋予轴可变的刚度。还公开了在可膨胀气球附接到导管的接合处具有基本上低轮廓键的导管。低轮廓接合是通过围绕轴的远端的圆周延伸的凹槽，杆的近端和远端以及尖端的近端产生的。具有低轮廓接合的导管可选地具有可缩回或嵌入的芯线。在实例中，导管具有由润滑材料或亲水材料形成，共挤出或涂覆有至少一种组分。

17. 发明授权

US07550451B2 Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy 有权
标题翻译：孕激素受体调节剂具有增加的女性避孕和激素替代疗法的抗增生性活性
公开(公告)号：US07550451B2
公开(公告)日：2009-06-23
申请号：US10631967
申请日：2003-08-01
申请人： Alexander Hillisch , Walter Elger , Gerd Schubert , Birgitt Schneider , Gudrun Reddersen
发明人： Alexander Hillisch , Walter Elger , Gerd Schubert , Birgitt Schneider , Gudrun Reddersen
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： C07J41/0083 , A61K31/565 , A61K31/566 , A61K45/06 , C07J1/00 , Y10S514/814 , A61K2300/00
摘要： The invention relates to new compounds of general formula I, their production and pharmaceutical preparations that contain these compounds. The compounds according to the invention are preferably used for female birth control and for HRT.
摘要翻译：本发明涉及通式Ⅰ的新化合物，它们的生产和含有这些化合物的药物制剂。根据本发明的化合物优选用于女性避孕和HRT。

18. 发明授权

US07550296B2 Generation of replication competent viruses for therapeutic use 失效
标题翻译：产生用于治疗用途的复制合格病毒
公开(公告)号：US07550296B2
公开(公告)日：2009-06-23
申请号：US11288821
申请日：2005-11-28
申请人： Terry Hermiston , Fang Jin , Peter Kretschmer
发明人： Terry Hermiston , Fang Jin , Peter Kretschmer
IPC分类号： A61K39/17 , A61K39/205 , A61K39/00 , A61K39/285 , A61K39/23 , C12N15/64 , C12N15/74 , C07H21/02 , A61K39/116
CPC分类号： C12N15/86 , A61K35/13 , A61K38/45 , A61K48/0091 , C07K14/005 , C12N7/00 , C12N2710/10321 , C12N2710/10343 , C12N2710/10361 , C12N2770/20022 , C12N2800/90 , C12N2830/42 , C12Q1/6897 , C12Q1/701
摘要： The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.
摘要翻译：本发明涉及具有治疗效用的具有复制能力的病毒的产生。本发明的复制型病毒可以表达可用于治疗疾病的蛋白质。

19. 发明授权

US07547721B1 Near infrared fluorescent contrast agent and fluorescence imaging 失效
标题翻译：近红外荧光造影剂和荧光成像
公开(公告)号：US07547721B1
公开(公告)日：2009-06-16
申请号：US10149917
申请日：1999-12-15
申请人： Naoto Miwa , Michihito Inagaki , Hiroaki Eguchi , Masafumi Okumura , Yoshio Inagaki , Toru Harada
发明人： Naoto Miwa , Michihito Inagaki , Hiroaki Eguchi , Masafumi Okumura , Yoshio Inagaki , Toru Harada
IPC分类号： A61K31/404
CPC分类号： A61K49/0032 , A61K49/0021
摘要： The present invention relates to a compound defined by a formula herein, a composition and/or a method relating to one or more of the defined compounds.
摘要翻译：本发明涉及由本文公式定义的化合物，与一种或多种所定义化合物有关的组合物和/或方法。

20. 发明授权

US07517894B2 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US07517894B2
公开(公告)日：2009-04-14
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式